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ARTICLE SUMMARY 
- Individualized survivorship care plans can be generated using clinical data routinely 
submitted to a central registry of HCT recipients  
- These care plans reduced cancer and treatment distress and improved mental domain of QOL 
in a randomized study of long-term HCT survivors 
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ABSTRACT 
Survivorship care plans may facilitate long-term care for cancer survivors, but their effectiveness 
has not been established in hematopoietic cell transplantation recipients. We evaluated the 
impact of individualized survivorship care plans on patient-reported outcomes among transplant 
survivors. Adult (≥18 years at transplant) survivors who were 1-5 years post-transplantation, 
proficient in English, and without relapse or secondary cancers were eligible for this multicenter 
randomized trial. Care plans were developed based on risk-factors and treatment exposures using 
patient data routinely submitted by transplant centers to the Center for International Blood and 
Marrow Transplant Research and published guidelines for long-term follow-up of transplant 
survivors. Phone surveys assessing patient-reported outcomes were conducted at baseline and 6-
months. Primary endpoint was confidence in survivorship information, and secondary endpoints 
included cancer and treatment distress, knowledge of transplant exposures, health care utilization 
and health-related quality of life. Of 495 patients enrolled, 458 completed a baseline survey and 
were randomized (care plan=231, standard care=227); 200 (87%) and 199 (88%) completed the 
6-month assessments, respectively. Patient characteristics were balanced in the two arms.  
Participants on care plan arm reported significantly lower distress scores at 6-months and an 
increase in the Mental Component Summary quality of life score assessed by the SF12 
instrument. No effect was observed on the endpoint of confidence in survivorship information or 
other secondary outcomes. Provision of individualized survivorship care plans generated using 
registry data was associated with reduced distress and improved mental domain of quality of life 
among 1-5 year hematopoietic cell transplantation survivors. (clinicaltrials.gov NCT02200133) 
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INTRODUCTION 
It is estimated that there will be 250,000 hematopoietic cell transplantation (HCT) survivors in 
the United States (US) by 2020.1 Patients who survive the period of early complications and 
disease relapse, generally 1-2 years after transplantation, can expect high probability of 
subsequent long-term survival.2-7 Although potentially cured of their underlying disease, HCT 
survivors continue to be at risk for late complications that can cause substantial morbidity, 
mortality, and functional deficits, and contribute to psychosocial and quality of life 
impairments.8-23 Established survivorship guidelines provide a pragmatic approach to the long-
term follow-up of autologous and allogeneic HCT survivors by recommending a minimum set of 
screening and preventive evaluations that need to be performed periodically post- 
transplantation.24,25 
 
HCT survivors frequently do not receive or adhere to preventive care guidelines.26-28 Many 
barriers contribute to the inadequate provision of coordinated patient-centric survivorship care in 
this patient population.29-31 Among these barriers, lack of awareness of exposures and risks by 
patients is strongly associated with a lower likelihood of adherence to preventive care 
recommendations.26 Additionally, both transplant and non-transplant providers cite lack of 
knowledge of late complication risks and of awareness of  guidelines as barriers to providing 
adequate preventive care.32 Finally, capacity limitations at transplant centers may impede 
provision and coordination of preventive care to HCT survivors.29,33-35   Interventions to enhance 
patient awareness of preventive care could potentially enhance appropriate healthcare utilization 
and adherence to survivorship guidelines, although, this approach has not been previously tested.  
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A treatment summary and survivorship care plan (SCP) is a tool that provides cancer survivors 
with information on their cancer type, treatments and potential consequences, and 
recommendations regarding follow-up and preventive care. SCPs are generally accepted as an 
important component of cancer survivorship care.36 Randomized trials of SCPs in cancer patients 
have primarily focused on providing information through in-person visit with patients or 
educating primary care providers, and evidence of their efficacy in enhancing various aspects of 
cancer survivorship care is generally negative.37 They are also frequently underutilized for many 
reasons, including insufficient resources for their generation and implementation, and a paucity 
of evidence regarding an impact on patient outcomes.38-42 The use and dissemination of SCPs in 
HCT survivors are hampered by similar challenges, and many transplant centers do not routinely 
provide patients with this tool. Furthermore, these barriers may be accentuated given the highly 
complex nature and unique exposures associated with the transplant procedure and challenges 
that exist in providing coordinated survivorship care.29    
 
We hypothesized that a patient centered approach with a personalized SCP based on published 
guidelines for prevention of HCT-related late complications,24,25 and generated using patient data 
routinely submitted by transplant centers in the US to an international clinical outcomes registry 
(Center for International Blood and Marrow Transplant Research [CIBMTR]) would increase 
patient awareness of recommended preventive care, which in turn would reduce distress, 
promote healthy behaviors, enhance healthcare utilization for appropriate preventive care, and 
improve health related quality of life (HRQOL). By using existing CIBMTR data, this approach 
would overcome several system-level barriers to providing survivorship care through transplant 
centers. Furthermore, it could serve as a template for a generalizable and efficient mechanism for 
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providing a patient-centric SCP to long-term HCT survivors who frequently are no longer under 
the care of transplant centers and are particularly vulnerable to gaps in preventive care. In a 
multicenter randomized controlled trial (RCT), we evaluated the efficacy of such an 
individualized SCP instrument generated using registry data and mailed to patients versus 
standard care on improving patient reported outcomes in adult HCT survivors who were 1-5 
years after their transplantation. 
 
METHODS 
Supplemental materials detail study methods. Briefly, potentially eligible patients from 17 
participating US centers were identified from the CIBMTR database and their data were used to 
generate a paper-based SCP that was personalized to their HCT specific exposures (see 
Supplemental Materials).43 Patient eligibility criteria were kept broad and included patients who 
were 1-5 years post-transplant, ≥18 years at the time of HCT, with no evidence of disease 
relapse/progression or second cancers, and fluency in English; patients were eligible irrespective 
of transplant type (autologous or allogeneic), diagnosis, donor source or conditioning regimen. 
None of the participating centers had an existing mechanism for routinely providing SCPs to 
their patients.  The RCT used a multi-center design with patient-level randomization to treatment 
(Figure 1), and was approved by Institutional Review Boards at the NMDP and each 
participating site. A random order list of survivors was generated and released in blocks to 
centers, who confirmed patient survival and accuracy of SCP related data. Centers contacted and 
consented patients and then informed the CIBMTR, who proceeded with the rest of the study 
procedures. The CIBMTR Survey Research Group (SRG) conducted a phone assessment within 
30 days of receiving participant enrollment form. Patients were randomized 1:1 to the SCP or 
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control arm (with delayed SCP). Patients randomized to the SCP arm were express mailed an 
information letter and their printed SCP while patients on the control arm received an 
information letter only. SRG then contacted all enrolled patients by phone between 7-28 days of 
mailing study materials to conduct a health literacy assessment using the Newest Vital Sign.44 
During this contact, patients on the SCP arm were given the opportunity to address any questions 
about the content or use of their SCP. No further contact was made till the 6-month phone 
survey. The Confidence in Survivorship Information (CSI) was the primary endpoint 
(Supplemental Table 1).45 Secondary endpoints focused on Cancer and Treatment Distress 
(CTXD),20,46 as well as measures of Knowledge of Transplant Exposures, Health Care 
Utilization,26 and HRQOL using the SF-12.47 Patients on the intervention arm also received a 12-
item assessment for qualitative feedback on SCP utilization. Sample size calculations were 
performed using a standard error formula that allowed for possible variability in treatment effect 
across centers and considered dropouts from baseline to 6 months. Our enrollment goal was 495 
patients, which yielded adequate power to detect standardized effect sizes of ≥0.3, which are 
considered to be clinically meaningful, and anticipated a 10% drop-off from baseline to 6-
months. An intention-to-treat approach was followed for analysis. A mixed model with center-
level random effects and a fixed treatment effect was used to test whether a change in baseline 
and 6-month existed between the treatment and control groups for the primary and secondary 
endpoints. The 6-month assessment was used as a response variable and the baseline assessment 
was used as an explanatory variable in the regression models. If a treatment effect existed, we 
further evaluated whether the effect was modified by demographic variables or any interactions 
between variables.  
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RESULTS 
Patient Characteristics 
Among the 495 patients enrolled, 458 completed the baseline survey and were randomized 
(SCP=231, control=227); 200 (87%) and 199 (88%) completed 6-month assessments, 
respectively (Figure 2). The main reasons for dropout were loss to followup or patients not 
eligible for followup assessment due to interim disease relapse or progression. A greater 
proportion of patients who completed the 6-month assessment were White and reported higher 
health literacy scores; otherwise there were no significant differences in the demographic 
characteristics of patients who did and did not complete the 6-month assessments (Supplemental 
Table 2). Patient and transplant characteristics (including health literacy scores) were well 
balanced between the two arms, except for sex (49% males in SCP compared to 60% in controls, 
P=0.01) (Table 1). Median age was 59 years in both arms and enrolled patients were 
predominantly White (96% SCP and 92% controls). In the SCP and control arms, 48% and 44% 
had received allogeneic HCT; among allogeneic HCT recipients 63% and 67% had a history of 
acute GVHD and 60% and 66% had a history of chronic graft-versus-host disease (GVHD), 
respectively.  
 
Analyses of Primary and Secondary Endpoints 
Of the 458 patients randomized to the two arms, 399 completed 6-month assessments, including 
398 who completed pre- and post-measurements for the primary endpoint (Table 2). We did not 
find any association between the SCP intervention and change in CSI scores from baseline to 6-
months (P=0.223), even after assessing for the effect of demographic factors and interactions. 
However, we did observe a significant decrease in CTXD scores (P=0.004) and increase in 
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HRQOL Mental Component Summary (MCS) scores as assessed by SF-12 (P=0.003) among 
patients randomized to the SCP arm. There was no association between the SCP intervention and 
other secondary endpoints.  
 
We further assessed the effect of demographic variables and interactions for the endpoints of 
CTXD and SF-12 MCS, where a significant treatment effect was observed. Age was significantly 
associated with CTXD scores (regression estimate -0.006, standard error 0.002; P=0.001), with 
lower distress among older patients. However, there was no significant interaction between age 
and SCP intervention and adjustment for age did not modify the treatment effect. The decrease in 
CTXD score for the SCP arm was independent of sex, health literacy, diagnosis, transplant type, 
and GVHD status (including acute and chronic GVHD). We also found a similar effect of age on 
MCS scores with older patients reporting significantly higher scores (estimate 0.03, standard 
error 0.034; P<0.001) and there was a significant interaction between age and SCP intervention 
(P=0.012). However, increase in mean MCS score in the SCP arm was independent of sex, 
health literacy, diagnosis, transplant type, and GVHD status.  
 
Utilization of SCP 
At their 6-month end-of-study assessments, patients on the intervention arm were asked 
questions about usefulness of the SCP for their survivorship care (Figure 3). A relatively large 
proportion of survivors reported that they found SCP somewhat or very useful for helping them 
better understand their HCT and related treatments (70%), side effects of HCT (65%), and 
managing their health (69%). The SCP helped survivors better communicate about HCT and its 
side effects with their medical providers. The 6-month interview included an open-ended 
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question about patients experience with the SCP; dominant themes identified on qualitative 
analyses included patients reporting that SCP helped survivors focus on their overall health, 
supported them in making care decisions with providers, and supported emotional health and 
coping.  
 
DISCUSSION 
In this large multicenter RCT of HCT survivors 1-5 years post-transplantation, we demonstrate 
that SCPs generated using a centralized clinical registry (CIBMTR), individualized to patient 
exposures, and without clinician contact to interpret or personalize their content and 
recommendations, are feasible and have desirable outcomes including lower treatment-related 
distress and improved mental health domain of HRQOL. Our results support further research 
towards broader implementation of our SCP instrument for facilitating care of HCT survivors 
and provides evidence to support a patient centered approach towards administration of SCPs.  
 
SCPs have been endorsed as a tool for facilitating the care of cancer survivors with the goal of 
improving patient outcomes by promoting care-coordination, shared-decision making, self-
management, and adherence to treatment recommendations.36,48 Evidence on their efficacy in 
impacting patients outcomes is mixed, and SCPs have not been universally adopted due to other 
barriers such as lack of standardized templates, need for extensive resources and time for their 
generation, and lack of reimbursement for their implementation.42,48-50 Similar challenges exist 
for transplant centers, and many programs have capacity limitations that frequently prevent 
provision of personalized comprehensive SCPs to their patients. Our SCP procedure provides 
several advantages to patients and transplant centers. It uses data that centers routinely submit 
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electronically to the CIBMTR and will provide a resource-effective mechanism for centers to 
generate the SCP for their recipients. Instead of receiving a generic SCP, patients can receive one 
that is specific to their treatment exposures. Our approach of facilitating patient ownership of 
survivorship care is different from the prevalent non-transplant cancer literature where SCPs 
have been largely tested in the setting of clinicians providing them to patients.37 Our SCP 
instrument was in a paper-based format and mailed to patients; more general dissemination 
would require its translation into an electronic format. Hence, further research is still needed to 
guide its implementation. An ongoing project funded by the National Cancer Institute is 
investigating its use in combination with an online health informatics platform to facilitate a self-
management program for selected late complications among HCT survivors (NCT03125070; 
Syrjala, Baker and Majhail).  
 
Of note, we did not observe any impact of the SCP intervention on our primary endpoint of CSI. 
Our study population consisted of HCT survivors who were relatively early post-transplantation 
(1-5 years) and enrolled by centers with an interest in providing survivorship care to their 
transplant recipients; it is possible our instrument may be more effective in enhancing knowledge 
and confidence about follow-up care among patients who are further out from transplantation or 
those who are not followed primarily or closely by their transplant centers. The CSI instrument 
has been validated in cancer survivors but not among HCT recipients, and it is also possible that 
it did not adequately measure the underlying construct in our patient population. The six-month 
pre- and post-intervention follow-up period was most likely too short to detect any significant 
associations with changes in healthcare adherence or utilization. We did not observe any 
interaction of GVHD with the intervention and study outcomes. This was most likely due to our 
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study population being relatively further out from transplantation and the short duration of the 
intervention. Furthermore, it is likely that patients with GVHD were under the active care of 
transplant centers and this may have impacted patient reported outcomes assessed in our study 
(e.g., greater confidence in recommended care, less distress, etc.). These same factors were 
probably responsible for some patients not finding the SCP tool to be useful for various aspects 
of survivorship care (see Figure 3; “I have not done this” and “Not at all useful” responses on 
SCP utilization survey administered as part of end-of-study assessments for the intervention 
arm).  
 
The concordant findings of reduction in CTXD scores and improvement in SF-12 MCS scores 
cross-validate the overall effect of SCP on reducing distress and improving HRQOL in our study 
population of HCT survivors. It is important to note that these effects occurred over a relatively 
short period of time and did not require any additional clinical contact or intervention to facilitate 
the use of the SCP. Interestingly, we found an independent association between older age and 
lower CTXD scores, which is consistent with other literature where older adults are less 
distressed about cancer and survivorship.51-54 The SCP provided concise information on previous 
treatments and potential late effects, and practical guidance regarding recommended preventive 
care that survivors could easily understand and share, which may have empowered them in the 
CTXD domains (e.g., uncertainty, health burden and medical demands) and MCS domains (e.g., 
mental health, social functioning, role-emotional), leading to the improvement in those areas.55   
 
Some limitations of our study must be acknowledged. First, the treatment summary portion of 
our SCP primarily included HCT-related and post-transplant events and did not have detailed 
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information on pre-transplant exposures as those data are not captured comprehensively by the 
CIBMTR. However, transplant centers have the option to add information about those exposures 
to the basic template of the SCP. Participants who completed 6-month assessments were more 
likely White and had higher health literacy, which may limit the generalizability of our findings. 
However, this is reflective of the prevailing healthcare disparities in HCT and research on other 
interventions to facilitate SCP use in this underserved population is needed.56 Notwithstanding 
these limitations, the pragmatic nature of our study eligibility criteria and schema will make our 
results broadly applicable to transplant centers in the US.  
 
An ideal mechanism to provide SCPs to HCT survivors would involve a dynamic, adaptable, and 
patient-specific shared-decision making approach between patients, their transplant centers, and 
other providers. However, several challenges prevent centers from providing this tool to facilitate 
survivorship care for their patients and SCPs that can be generated efficiently and without 
requiring significant center resources would be impactful for patient care. Our study supports 
further implementation of an individualized SCP generated using CIBMTR data in a population 
of HCT survivors that is at significant risk for late morbidity and mortality. Future research will 
examine the role of the SCP instrument in preventing specific late complications, in facilitating 
care coordination, and will serve as a platform for investigating novel methods for survivorship 
care delivery and implementation. 
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Table 1. Baseline characteristics of patients enrolled on the study 
 
Characteristic SCP (N=231) 
Routine care 
(N=227) 
Age at HCT, years; Median (range) 59 (19-81) 59 (20-77) 
Time from HCT to enrollment (months); Median (range) 42 (16-66) 45 (16-66) 
Age group at baseline survey, years; N (%)   
   18-29 7 (3) 9 (4) 
   30-39 10 (4) 14 (6) 
   40-49 28 (12) 18 (8) 
   50-59 55 (24) 58 (26) 
   60-69 83 (36) 92 (41) 
   ≥70 48 (21) 36 (16) 
Sex; N (%)   
   Male 112 (49) 136 (60) 
   Female 119 (52) 91 (40) 
Ethnicity; N (%)   
   Hispanic/Latino 8 (3) 7 (3) 
   Non-Hispanic/Latino 216 (94) 216 (95) 
   Declined 7 (3) 4 (2) 
Race; N (%)   
   White  222 (96) 208 (92) 
   African-American 5 (2) 15 (7) 
   Asian 2 (1) 3 (1) 
   Pacific Islander 1 (<1) 0 (0) 
   Declined 1 (<1) 1 (<1) 
Diagnosis; N (%)   
   Acute myeloid leukemia  52 (23) 46 (20) 
   Acute lymphoblastic leukemia 10 (4) 8 (4) 
   Myelodysplastic/myeloproliferative disorders 19 (8) 23 (10) 
   Chronic myeloid leukemia 2 (1) 3 (1) 
   Hodgkin lymphoma 13 (6) 10 (4) 
   Non-Hodgkin lymphoma 49 (21) 47 (21) 
   Plasma cell disorder/multiple myeloma 78 (34) 80 (35) 
   Other 8 (3) 10 (4) 
Time from diagnosis to HCT, months; Median (range) 7 (1-266) 8 (1- 327) 
Year of transplant; N (%)   
   2010 11 (5) 22 (10) 
   2011 67 (29) 61 (27) 
   2012 48 (21) 53 (23) 
   2013 81 (35) 64 (28) 
   2014 24 (10) 27 (12) 
26 
 
Transplant type; N (%) 
  
   Allogeneic 111 (48) 100 (44) 
   Autologous 120 (52) 127 (56) 
Donor type; N (%)   
   Allogeneic, related 47 (20) 36 (16) 
   Allogeneic, unrelated/umbilical cord blood 64 (28) 64 (28) 
   Autologous 120 (52) 127 (56) 
Graft type; N (%)   
   Bone marrow 15 (7) 16 (7) 
   Peripheral blood 207 (90) 203 (89) 
   Umbilical cord blood  9 (4) 8 (4) 
Number of transplants; N (%)   
   1 206 (89) 191 (84) 
   ≥2 25 (11) 36 (16) 
Conditioning regimen intensity; N (%) 
  
   Myeloablative (including autologous regimens) 168 (73) 176 (78) 
   Non-myeloablative/Reduced-intensity 62 (27) 50 (22) 
   Missing 1 (<1) 1 (<1) 
TBI as part of conditioning regimen; N (%)   
   Yes 49 (21) 46 (20) 
   No 182 (79) 181 (80) 
History of acute GVHD; N (%)*   
   Yes 70 (63) 67 (67) 
   No 41 (37) 33 (33) 
History of chronic GVHD; N (%)*   
   Yes 67 (60) 66 (66) 
   No 44 (40) 34 (34) 
Health Literacy; N (%)† 
  
   Adequate literacy 154 (74) 172 (83) 
   Possibility of limited literacy 36 (17) 27 (13) 
   High likelihood of limited literacy 18 (9) 9 (4) 
 
SCP – survivorship care plan; HCT – hematopoietic cell transplantation; TBI – total body irradiation; GVHD – 
graft-versus-host disease 
 
* Allogeneic HCT only 
† Assessed by Newest Vital Sign instrument; N=208 for SCP arm and N=208 for routine care arm 
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Table 2: Analysis for primary and secondary endpoints 
 
Endpoint* 
Mean (Standard 
Deviation) 
Estimate 
(Standard 
Error)# 
P-
value# 
Baseline 6-months 
Confidence in 
Survivorship Information† 
SCP (N=199) 1.44 (0.34) 1.50 (0.34) -0.034 (0.028) 0.223 
Routine care (N=199) 1.40 (0.38) 1.44 (0.39) 
  
Cancer and Treatment 
Distress‡ 
SCP (N=199) 0.91 (0.61) 0.78 (0.59) 0.123 (0.042) 0.004 
Routine care (N=198) 0.91 (0.64) 0.91 (0.69) 
  
Knowledge of Transplant 
Exposures† 
SCP (N=200) 0.86 (0.18) 0.87 (0.16) -0.018 (0.013) 0.182 
Routine care (N=198) 0.88 (0.15) 0.86 (0.16) 
  
Health Care Utilization† SCP (N=200) 0.80 (0.14) 0.80 (0.15) 0.014 (0.010) 0.149 Routine care (N=198) 0.80 (0.14) 0.82 (0.13) 
  
SF12: Physical Component 
Summary†  
SCP (N=200) 46.1 (10.3) 46.2 (10.6) -0.368 (0.638) 0.565 
Routine care (N=198) 46.0 (9.8) 45.8 (10.1) 
  
SF12: Mental Component 
Summary†  
SCP (N=200) 53.9 (7.6) 54.7 (7.0) -8.907 (3.009) 0.003 
Routine care (N=198) 53.9 (7.9) 53.4 (8.8) 
  
 
* N represents number who completed both baseline and 6-month assessments  
# Estimate and P-value based on analysis of covariance model with center-level random effects where any 
differences between the treatment groups were measured after adjustment for patients’ baseline 
measurement; where applicable, estimates were adjusted for demographic variables and/or interactions (see 
Methods section) 
† Higher score better 
‡ Lower score better 
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FIGURE LEGENDS 
Figure 1: Study schema 
Figure 2: CONSORT diagram 
Figure 3: Patient reported assessment of usefulness of SCP intervention (N=201 respondents on 
SCP arm who completed 6-month end-of-study assessments) 
 
 
 
 



  
SUPPLEMENTAL MATERIALS 
 
Randomized Trial of Individualized Treatment Summary and Survivorship Care Plan for 
Hematopoietic Cell Transplantation Survivors 
 
  
DETAILED METHODS 
 
Patients 
Seventeen US transplant centers that report autologous and allogeneic HCT to the CIBMTR and 
representing diverse location and size participated in the study. Potentially eligible patients from 
participating centers were identified from the CIBMTR. The CIBMTR is a research 
collaboration between the National Marrow Donor Program (NMDP)/Be The Match in 
Minneapolis, Minnesota and the Medical College of Wisconsin in Milwaukee, Wisconsin. By 
law in the US, transplant centers are required to submit data on all allogeneic HCTs to the 
CIBMTR. Additionally, approximately 80% of the national autologous HCT activity is captured 
by the registry. Computerized checks for discrepancies, physicians’ review of submitted data and 
on-site audits of participating centers ensure data quality. Centers submit Transplant Essential 
Data (TED) on all recipients before transplant, at 100 days and six months after transplant, 
annually until 6 years, and every other year thereafter, or until death. These data were used to 
generate the treatment summary including information on patient diagnosis and stage, donor and 
graft source, and transplantation procedure (e.g., conditioning regimen). HCT specific exposures 
that determine follow-up and preventive evaluations (age, sex, transplant type, exposure to total 
body irradiation [TBI], exposure to corticosteroids, and graft-versus-host disease [GVHD]) were 
abstracted from TED and were used to develop the personalized care plan for each patient.  
 
To maximize generalizability, patient eligibility criteria were intentionally kept broad (≥18 years 
at the time of HCT, recipients of autologous or allogeneic transplantation, with no evidence of 
relapse, disease progression or secondary cancers, any diagnosis, donor or graft source, and any 
conditioning regimen). Patients had to be 1-5 years from their transplant, in order to focus on a 
group of survivors who are frequently no longer under the direct care of transplant centers and 
are most vulnerable to receive inadequate HCT specific-survivorship and preventive care. 
Participants could have received more than one HCT. Participants had to be fluent in English so 
that they could complete study assessments.   
 
Only centers without an existing mechanism for routinely providing SCPs to their patients were 
invited to participate in our study. Information on prevalent practices for caring for autologous 
and allogeneic HCT long-term survivors, including templates for discharge summaries and any 
routine communications with patients and their local providers, was requested form centers and 
was reviewed by study investigators to confirm their eligibility to participate and enroll patients. 
Participating centers also committed to not providing patients a SCP during routine post-
transplant care and outside the context of this study during the enrollment and follow up period.   
 
SCP Template 
We have previously reported on the development of an individualized SCP instrument generated 
using CIBMTR registry data and specifically targeted for use by HCT survivors.1 Briefly, a draft 
paper-based template for the SCP was generated by the investigators and consisted of three 
elements: an introductory page with information on appropriate use of the SCP, a treatment 
summary with diagnosis and transplant information electronically abstracted from CIBMTR 
data, and a care plan that listed recommended preventive evaluations based on published 
guidelines and patient specific exposures (age, sex, transplant type, exposure to TBI or steroids, 
or occurrence of GVHD). To obtain qualitative feedback on content and formatting of the SCP, 
phone focus groups were conducted with HCT survivors/caregivers (3 focus groups, N=22 
participants), HCT physicians and advanced practice providers (2 focus groups, N=14 
participants), hematology-oncology and primary care physicians and advanced practice providers 
(3 focus groups, N=24 participants), and HCT nurses and social workers (4 focus groups, N=17 
participants). Qualitative analyses identified patient-centered elements that informed the 
generation of the final SCP templates used as the intervention in the RCT.1 A sample SCP 
template is available as part of Supplemental Materials.   
 
Study Procedures 
The RCT used a multi-center design with patient-level randomization to treatment (Figure 1). The 
RCT was reviewed and approved by Institutional Review Boards (IRBs) at the NMDP and each 
participating site and was registered on clinicaltrials.gov (NCT02200133). To minimize bias in 
patient enrollment, a random order list of potentially eligible 1-5 year survivors for each center 
was generated using the CIBMTR database and released in blocks of 10-20 patients. Center 
coordinators then reviewed medical records to confirm patient survival, disease status, and 
accuracy of SCP related research data that had been submitted by the center to the CIBMTR. 
Centers contacted patients by phone and presented the study, and then mailed an information 
packet to patients who agreed to consider participation; some center IRBs required a mailed 
letter/post-card with an opt in/opt out option, followed by mailing of the information packet to 
patients who opted in or with follow-up phone calls if no response to the mailing was received. 
On receiving the signed informed consent form from patients, transplant centers informed the 
CIBMTR, who then proceeded with the rest of the study procedures.  
 
The CIBMTR Survey Research Group (SRG) conducted a baseline assessment by phone within 
30 days of receiving a completed participant enrollment form and contact information from the 
transplant center. CIBMTR data were then used to generate personalized SCPs for all consenting 
patients. Patients were randomized 1:1 to either the SCP arm or standard care with delayed SCP 
(control) arm. Since centers may preferentially follow long-term allogeneic HCT survivors, 
patient enrollment was weighted such that at least one-third of the cohort consisted of autologous 
HCT recipients. Patients randomized to the SCP arm were express mailed an information letter 
and their printed SCP from the CIBMTR, while patients on the control arm received only an 
information letter. All patients received a phone call from the CIBMTR SRG between 7-28 days 
of mailing study materials to conduct a health literacy assessment using the Newest Vital Sign.2 
During this phone contact, patients on the SCP arm were also given the opportunity to ask and 
address any questions about the content or use of their SCP. No further contact was made with 
patients till their 6-month outcomes phone survey conducted by the CIBMTR SRG. After 
completing their end-of-study assessments, printed SCPs were provided to patients in the control 
arm. Study accrual began in April 2015 and the last patient was enrolled in June 2016. Patients 
were not offered any compensation for participating on the study.  
 
Assessments 
Supplemental Table 1 describes our study instruments, including their psychometric properties. 
The Confidence in Survivorship Information (CSI) was the primary endpoint. The CSI is a 13-
item questionnaire that uses a 3-point Likert scale of “not at all” to "very confident”.3 The 
instrument has two subscales, one that tests confidence in knowledge of past cancer diagnostic 
and treatment details (3 items, Cronbach’s α=0.77) and second that evaluates confidence in 
knowledge about prevention and treatment of long-term and late-effects of disease and treatment, 
prevention of disease recurrence, access to resources, and familial risk of cancer (10 items, 
Cronbach’s α=0.95). Internal consistency reliability for the CSI in our HCT sample at baseline 
was α=0.87. Secondary endpoints focused on Cancer and Treatment Distress (CTXD), a 23 item 
instrument validated in HCT recipients that assesses distress and worry specific to HCT and 
associated complications,4,5 as well as measures of Knowledge of Transplant Exposures 
(developed by study investigators), Health Care Utilization,6 and HRQOL using the SF-12.7 The 
phone-administered assessments required 30-45 minutes to complete.  Patients on the 
intervention arm also received an investigator developed 12-item assessment that obtained 
qualitative feedback on patient utilization of the SCP at the 6-month assessment.     
 
Statistical Analysis  
Sample size and power calculations were performed using a standard error formula that allowed 
for possible variability in treatment effect across centers and considered dropouts from baseline to 
6 months. Our targeted enrollment goal was 495 patients, which yielded adequate power to detect 
standardized effect sizes of ≥0.3, which are considered to be clinically meaningful, and 
anticipated a 10% drop-off from baseline to 6-months. An intention-to-treat approach was 
followed for analysis.  
 
Baseline characteristics between the two groups were compared using Chi-square tests for 
categorical variables and t-tests for continuous variables. A mixed model with center-level 
random effects and a fixed treatment effect was used to test whether a change in baseline and 6-
month existed between the treatment and control groups for the primary and secondary endpoints. 
The model, in addition to accounting for center-to-center variation (center effect), allowed for 
patient responses to be correlated within centers. The 6-month assessment was used as a response 
variable and the baseline assessment was used as an explanatory variable in the regression 
models. If a treatment effect existed, we further evaluated whether the effect was modified by 
demographic variables (including age, sex, transplant type, acute and/or chronic GVHD, 
diagnosis, and health literacy), or any interactions between variables. Given the short time period 
projected for accrual and the low risk of adverse events, no interim analyses were planned. 
Analyses were performed using SAS software (Version 9.4). All P-values reported are two-sided 
and P<0.05 was considered significant.  
 
Data Sharing Statement 
The study was funded by Patient Centered Outcomes Research Institute (PCORI), and their data 
sharing policy applies (www.pcori.org). 
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Supplemental Table 1: Study assessments and patient reported outcome measures  
 
Instrument Description Items Time 
point 
Estimated 
Time to 
complete 
Confidence in 
Survivorship 
Information 
(CSI)1  
Assesses confidence in knowledge of past cancer 
diagnostic/treatment details and confidence in knowledge 
about prevention/treatment of late complications, prevention 
of future disease, access to resources and familial risk of 
cancer. This 13-item patient self-reported tool assesses 
confidence in knowledge of past cancer diagnostic and 
treatment details (3 items; Cronbach's alpha = 0.77) and 
confidence in knowledge about prevention and treatment of 
long term and late-effects of disease and treatment, prevention 
of future disease, access to resources, and familial risk of 
cancer (10 items; Cronbach's alpha = 0.95). The scale uses a 
3-point scale ranging from "not at all" to "very confident" in 
each knowledge item. Sample items include "I am confident 
in the stage of cancer I have/had" and "I am confident in 
strategies for treating long term physical effects of cancer". 
Higher score indicates greater confidence in knowledge of 
treatment details and preventive recommendations.   
13 Baseline 
6 mos 
2 mts 
Cancer and 
Treatment 
Distress 
(CTXD)2-5 
Assesses distress or worry specific to HCT and associated 
complications using items such as “costs of healthcare”, 
“possibility of relapse” and “being a burden to other people”; 
subscales include uncertainty, family strain, medical system 
demands, health burden, finances and impact on function. 
Response options can range from 0 (“none”) to 3 (“severe”), 
and the scores represent the mean response across the 
scale/subscale item. In an analysis of 701 HCT recipients, 
Syrjala et al reported strong internal consistency reliability at 
pre-transplant, and at day 100 and day 180 post-transplant 
(Cronbach α 0.94, 0.95 and 0.95, respectively). The mean 
scores (standard deviation) at the three time points were 1.12 
(0.60), 0.93 (0.60), and 0.85 (0.59), respectively. Subscale 
reliability was high across time (α >0.70), and there was 
strong correlation of pre-transplantation CTXD with post-
transplant CTXD. A higher score indicates higher level of 
distress among HCT recipients. Testing supports its value as a 
predictor of health outcomes and it has been in several 
randomized clinical trials.  
27 Baseline 
6 mos 
3 mts 
Knowledge of 
transplant 
exposures 
Investigator developed measure to assess knowledge of HCT 
exposures (conditioning type, TBI use, transplant type, donor 
type, GVHD). Higher score indicates greater knowledge of 
transplant exposures.  
5 Baseline 
6 mos 
2 mts 
Health 
Behaviors 
Standardized measures to assess health behaviors: Godin 
Leisure Time Exercise Q as a measure of minutes/week in 
moderate/vigorous activity (<150 as cutoff);6 Tobacco use 
(any as cutoff); 7,8 Alcohol use (≥ 1 drinks/day for women, ≥ 2 
drinks/day for men as cutoff);7,8 Sunscreen use (daily use of 
>SPF 30 sunscreen as cutoff);7,8 Diet (>2 fast food 
meals/week and <5 fruits and vegetables/day as cutoff);7,8 
Body Mass Index (>30 as cutoff)7,8 Health behaviors are 
31 Baseline 
6 mos 
8 mts 
  
scored as a sum from 0-7, with one point for each behavior: 
non-smoking, alcohol less than one glass a day for women or 
two glasses a day for men, moderate to vigorous physical 
activity ≥ 150 minutes a week, regular use of sunscreen of 
SPF ≥ 30, food intake of 5 servings of fruit and vegetables a 
day, body mass index ≤ 25, sleep averaging ≥ 7 hours a night. 
Item content is matched to NHANES or BRFSS for normative 
comparisons. Higher scores indicate positive health care 
behaviors.   
Health Care 
Utilization9 
Widely pretested measure of SCP recommended screening 
and preventive evaluations; scores range from 0-15 with 2 
gender specific items each. Scores are transformed to the 
proportion preventive care recommendations met as indicated 
on the SCP. Higher scores indicate greater and appropriate 
health care utilization for preventive care.  
26 Baseline 
6 mos 
4 mts 
SF-1210,11 Validated health quality of life 12-item sub-set of the MOS 
SF-36 which accurately reproduces the two summary 
component scores: Physical Component Summary Score 
(PCS) and Mental Health Component Summary Score (MCS). 
In the general population, the test-retest reliability has been 
reported to be 0.89 and 0.76 for the two scores, respectively. 
Studies have shown that the relative validity of SF-12 is 
comparable to the more comprehensive SF-36 quality of life 
instrument. The mean PCS scores for chronic health 
conditions are in the range of 40-45, while that for MCS range 
from 50-55; in comparison, the mean general population PCS 
and MCS scores are ~50 and ~50, respectively. Higher scores 
correspond to better health-related quality of life.  
12 Baseline 
6 mos 
3 mts 
Generalized 
Self-Efficacy 
scale12,13 
Assesses optimistic self-beliefs used to cope with a variety of 
demands in life known as self-efficacy, i.e., the belief that 
one’s actions are responsible for successful outcomes. The 
scaled score for each question ranges from 1 to 4. Higher 
scores indicate stronger patient’s belief in self-efficacy. 
10 Baseline 
6 mos 
2 mts 
Newest Vital 
Sign14 
Measures health literacy level using 1 scenario of an ice cream 
container nutrition label; 1 score (6 items) includes assessment 
of two main constructs, numeracy and reading 
comprehension. Higher score indicates greater health literacy.  
6 1-4 wks 2 mts 
Survivorship 
Care Plan 
Utilization 
Assessment 
Treatment-group participants will be asked whether they if 
they have any questions about the SCP and how they plan to 
use it. At the 6 month follow-up assessment, treatment-group 
participants will be asked how they did use their SCP and 
what they liked or did not like about it. 
5 1-4 wks 
6 mos 
3 mts 
HCT – hematopoietic cell transplantation; TBI – total body irradiation; GVHD – graft-versus-host disease; SCP – 
treatment summary and survivorship care plan; mos – months; mts – minutes  
 
 
References for study assessments: 
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Supplemental Table 2. Baseline characteristics of patients who completed the baseline 
assessments, and then either completed the study or dropped out/were excluded from the analysis  
 
Characteristic 
Completed 
study 
(N=399) 
Drop out/ 
excluded 
(N=59) 
P-
value 
Age at HCT, years; Median (range) 58.8 (19.4-81.1) 54.5 (20.2-77.2) 0.6760 
Time from HCT to enrollment (months); Median (range) 42.6 (15.7-66.3) 45.3 (17.3-63.8) 0.6760 
Age group at baseline survey, years; N (%)    
   18-29 12 (3.0) 4 (6.8) 0.1755 
   30-39 19 (4.8) 5 (8.5)  
   40-49 41 (10.3) 5 (8.5)  
   50-59 99 (24.8) 14 (23.7)  
   60-69 159 (39.9) 16 (27.1)  
   ≥70 69 (17.3) 15 (25.4)  
Sex; N (%)    
   Male 212 (53.1) 36 (61.0) 0.2667 
   Female 187 (46.9) 23 (39.0)  
Ethnicity; N (%)    
   Hispanic/Latino 13 (3.3) 2 (3.4) 0.4346 
   Non-Hispanic/Latino 375 (94.0) 57 (96.6)  
   Declined 11 (2.8) -  
Race; N (%)    
   White  380 (95.2) 50 (84.8) 0.0062 
   African-American 12 (3.0) 8 (13.6)  
   Asian 4 (1.0) 1 (1.7)  
   Pacific Islander 1 (0.3) -  
   Declined 2 (0.5) -  
Diagnosis; N (%)    
   Acute myeloid leukemia  90 (22.6) 8 (13.6) 0.0801 
   Acute lymphoblastic leukemia 15 (3.8) 3 (5.1)  
   Myelodysplastic/myeloproliferative disorders 40 (10.0) 2 (4.8)  
   Chronic myeloid leukemia 5 (1.3) -  
   Hodgkin lymphoma 16 (4.0) 7 (11.9)  
   Non-Hodgkin lymphoma 84 (21.1) 12 (20.3)  
   Plasma cell disorder/multiple myeloma 134 (33.6) 24 (40.7)  
   Other 15 (3.8) 3 (5.1)  
Time from diagnosis to HCT, months; Median (range)    
Year of transplant; N (%)    
   2010 28 (7.0) 5 (8.5) 0.5831 
   2011 112 (28.1) 16 (27.1)  
   2012 86 (21.6) 15 (25.4)  
   2013 125 (31.3) 20 (33.9)  
   2014 48 (12.0) 3 (5.1)  
  
Transplant type; N (%)    
   Allogeneic 191 (47.9) 20 (33.9) 0.0503 
   Autologous 208 (52.1) 39 (66.1)  
Donor type; N (%)    
   Allogeneic, related 77 (19.3) 6 (10.2) 0.0975 
   Allogeneic, unrelated/umbilical cord blood 114 (28.6) 14 (23.7)  
   Autologous 208 (52.1) 39 (66.1)  
Graft type; N (%)    
   Bone marrow 29 (7.3) 2 (3.4) 0.4685 
   Peripheral blood 356 (89.2) 54 (91.5)  
   Umbilical cord blood  14 (3.5) 3 (5.1)  
Number of transplants; N (%)    
   1 347 (87.0) 50 (84.8) 0.6809 
   ≥2 52 (13.0) 9 (15.3)  
Conditioning regimen intensity; N (%)    
   Myeloablative (including autologous regimens) 296 (74.2) 48 (81.4) 0.4533 
   Non-myeloablative/Reduced-intensity 101 (25.3) 11 (18.6)  
   Missing 2 (0.5) -  
TBI as part of conditioning regimen; N (%)    
   Yes 87 (21.8) 8 (13.6) 0.1449 
   No 312 (78.2) 51 (86.4)  
History of acute GVHD; N (%)*    
   Yes 123 (64.4) 14 (70.0) 0.8062 
   No 68 (35.6) 6 (30.0)  
History of chronic GVHD; N (%)*    
   Yes 119 (62.3) 14 (70.0) 0.6288 
   No 72 (37.7) 6 (30.0)  
Health Literacy; N (%)†    
   Adequate literacy 309 (80.1) 17 (56.7) 0.0112 
   Possibility of limited literacy 54 (14.0) 9 (30.0)  
   High likelihood of limited literacy 23 (6.0) 4 (13.3)  
 
SCP – survivorship care plan; HCT – hematopoietic cell transplantation; TBI – total body irradiation; GVHD – 
graft-versus-host disease 
 
*  Allogeneic HCT only 
†  Assessed by Newest Vital Sign instrument; N=386 for those retained and N=30 for those who dropped 
out/were excluded from the analysis 
 
 
 
 
 
 
 
 
 
  
Supplemental Appendix: Sample template for treatment summary and survivorship care plan 
used in the study.  
Blood and Marrow Transplant Survivor Treatment Summary 
For: [First name_Last name] 
Date Your Treatment Summary was Created:  [Month DD, YYYY] 
The information presented on this Treatment Summary comes from transplant-related data 
provided to the CIBMTR by your transplant center. There may be additional medical history that 
is relevant to you and important to share with your doctors and other medical care providers.
Your Medical Information 
Date of birth:  (text date) 
Sex: 
Diagnosis: 
Date of Diagnosis:      (date) 
Your Transplant Information 
Transplant center name: 
Address: (hospital) 
Phone number: (BMT program number) 
Date of transplant:   (date) 
Age at transplant:    (yrs) 
Transplant type: (autologous/allogeneic unrelated/allogeneic related) 
Cell source type: (bone marrow, peripheral stem cell, cord blood unit(s)) 
Prior transplant:  (yes/no) 
Date of most recent previous transplant:  (date or not applicable) 
Type of most recent previous transplant: (autologous / allogeneic / syngeneic(twin) or not 
applicable) 
Patient CIBMTR research ID (CRID): 
1 
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APPENDIX D: SURVIVORSHIP CARE PLAN AND STUDY FOLDER TEMPLATES
                   
  
  
Your Transplant Treatment 
Chemotherapy drugs received as part of the preparative regimen: (list or not applicable) 
 
Steroid drugs received as part of the preparative regimen (for example, prednisone): (list or not 
applicable) 
 
Total Body Irradiation (TBI):  (list dose and dose unit (cGy, Gy)/Yes/No) 
Graft versus Host Disease (GVHD) 
Drugs to prevent GVHD:   (yes/no/not applicable)  
                  
GVHD prevention drugs: (list or not applicable)  
 
Acute GVHD: (yes/no/ not applicable) 
Chronic GVHD: (yes/no/ not applicable) 
Date of chronic GVHD diagnosis: (text date or not applicable) 
 
Your Blood and Marrow Transplant Survivorship Care Plan 
Your survivorship care plan is based on research¹ and was developed by doctors and researchers 
from around the world. This information is not intended as medical advice and does not replace 
your transplant doctor’s recommendations. Your doctor may recommend or order other tests 
or evaluations on a different schedule based on your specific situation. Follow his or her 
recommendations carefully. 
In the table below, you’ll find information on the tests and evaluations that physicians 
commonly recommend for transplant recipients after transplant. Items in bold are found in the 
Glossary.  
The information below will help you: 
Patient CIBMTR research ID (CRID): 
2  
NMDP IRB Approved September 17, 2015 
  V7.0 
                   
  
  
• Understand what to expect at your checkup appointments, and  
• Discuss your questions or concerns with your doctor.  
There are questions you can ask your doctor to help you prepare for these tests and exams. Also, 
these questions will help you understand what the test results mean for you.  
Some questions to ask your doctors 
• Which tests and evaluations do I need to have more often? How often? 
• How should I prepare for my exam? How long will the tests take? 
• How long does it take to learn my test results? 
• Are my test results within an acceptable range for my age and situation?  
• How do I know when to call the clinic about symptoms I’m having?  
Your care plan is organized by parts of the body (for example, eyes, mouth, and heart). Each 
section includes more questions to ask your doctor that are specific to a body part. There is space 
for you to take notes in each section and at the end of the care plan.  
 
1 Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term survivors after 
hematopoietic cell transplantation; Center for International Blood and Marrow Transplant Research (CIBMTR), American 
Society for Blood and Marrow Transplantation (ASBMT), European Group for Blood and Marrow Transplantation (EBMT), 
Asia-Pacific Blood and Marrow Transplantation Group (APBMT), Bone Marrow Transplant Society of Australia and New 
Zealand (BMTSANZ), East Mediterranean Blood and Marrow Transplantation Group (EMBMT) and Sociedade Brasileira de 
Transplante de Medula Ossea (SBTMO). Co-published in Biol Blood Marrow Transplant. 2012; 18(3): 348-371; Bone Marrow 
Transplant (2012) 47, 337–341; and Hematol Oncol Stem Cel Ther 2012;5(1):1-30. 
You should share this care plan with your doctors. Also, if you need to go to urgent care or the 
emergency room, it is helpful to take the care plan with you. 
Patient CIBMTR research ID (CRID): 
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Summary of Recommendations for Your Preventive Care 
IMMUNE SYSTEM 
  Vaccines to prevent infection  
  Because you have a history of GVHD and if you are on immunosuppressant drugs, you might 
need to take antibiotics to prevent infections like pneumonia and meningitis, for as long as you 
are on immunosuppressant drugs, and before dental work 
  If you are on immunosuppressant drugs, you may need a test for Cytomegalovirus (CMV).  
EYES 
  Wear sunglasses every time you go outside. 
  Vision screening by your eye doctor 1 time every year to check how well you can see 
  Because you have a history of GVHD, you may need to have eye exams more often 
MOUTH 
  Because you have a history of GVHD and/or have received total body irradiation, you need to 
have mouth, teeth, tongue, and throat exam at least 2 times every year. Talk to your doctor and 
dentist about when you should have these check-ups.   
  Dental exam and tooth cleaning by a dentist at least 1 time every year.  Ask your doctor if you 
should take antibiotics before dental exams.   
LUNGS 
  Lung exam at least 1 time every year  
  Because you have a history of GVHD, you might need to have lung exams and pulmonary 
function tests more often. Talk to your doctor about when you should have these check-ups. 
  Don’t smoke or use tobacco. Stay away from places where people usually smoke. 
HEART AND BLOOD VESSELS 
 Blood pressure checked every time you visit the clinic  
  Blood tests to check your cholesterol level at least 1 time every year. This includes triglycerides, 
LDL, and HDL  
LIVER 
  Liver function blood tests (to see if your liver is working well) at least 1 time every year 
4 
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  If you had red blood cell transfusions, have a blood ferritin test to check the level of iron in your 
blood. 
KIDNEYS AND BLADDER 
  Blood pressure checked every time you visit the clinic  
  Kidney test at least 1 time every year which includes testing: protein levels in your urine  and 
nitrogen levels in your blood (BUN) and creatinine test 
  Because you have a history of GVHD, you might need to have your kidneys checked more often.  
MUSCLES AND JOINTS 
  If you have myopathy (weak muscles), muscle pain, or joint pain, schedule an appointment with 
your doctor right away. Your doctor will check your muscles to find out if you need treatment. 
  Because you have a history of GVHD and have taken steroids (such as prednisone), you may 
need clinical tests of muscle strength and range of motion in your joints 
BONES 
  Bone density scan (test) every year.  
SKIN 
  Do a self-exam of your skin every month to check for any changes (for example, rash, unusual 
growth, or patch).  
  Use sunscreen with SPF 15 or higher every time you go outside. Reapply at least every 2 hours, or 
more often if you’re sweating or in and out of the water. 
  Avoid direct sunlight. Wear a broad-brimmed hat or use a large umbrella to protect your skin. 
NERVOUS SYSTEM 
  Clinical exam by your doctor at least 1 time every year to check for changes or problems 
ENDOCRINE ORGANS (THYROID, GROWTH AND SEX HORMONES) 
  Blood test to check how well your thyroid is working  
  Blood tests to assess your sex hormone levels 
  Fasting glucose (sugar) test to check for Diabetes  
 
GENITALS AND SEXUAL HEALTH 
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  Discuss with your physician if you are experiencing sexual side effects such as vaginal dryness, 
pain with sex, or difficulty having an erection. 
  Gynecology exam at least 1 time every year 
FERTILITY AND FAMILY PLANNING 
  If you want to have children in the future, ask your doctor to refer you to a fertility doctor.  
EMOTIONAL HEALTH 
  Going through transplant is a very emotional experience. Your feelings and needs will change a 
lot, maybe even every day. It’s important that you talk openly and regularly with your doctor, 
family and friends. 
DIET AND NUTRITION 
  Eat a healthy diet 
  Keep yourself well hydrated 
  Avoid foods with lots of processed (fake) sugar or saturated (bad) fat like candy or soda 
GENERAL HEALTH 
  Use alcohol in moderation (less than 2 drinks a day) 
  Stay physically active (2.5 hours each week of moderate exercise)   
  Don’t smoke, stay away from second hand smoke, don’t use chewing tobacco  
NEW CANCER SCREENING 
Talk to your doctor about: 
  Breast cancer screening (mammography every 1 to 2 years starting at age 25)  
  Cervical cancer screening 
  Colorectal cancer screening (starting at age 50 or earlier if you have a family history of colorectal 
cancer) 
  Skin cancer screening 
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Your Blood and Marrow Transplant Survivorship Care Plan 
For: [First name_Last name]   
 
RECOMMENDATIONS FOR YOUR ROUTINE SCREENING AND PREVENTIVE CARE 
IMMUNE SYSTEM QUESTIONS TO ASK YOUR 
DOCTOR AND YOUR NOTES  
Even 5 years or more after transplant, you are at risk to get 
infections. This is because it takes time for your immune system to 
recover from transplant. You might also take medications that 
lower your body’s ability to fight disease.  
  Vaccines to prevent infection  
  Because you have a history of GVHD, you might need to take 
antibiotics: 
• To prevent infections like pneumonia and meningitis, for 
as long as you are on immunosuppressant drugs 
• Before dental work 
  If you are on immunosuppressant drugs, you may need a blood 
test for Cytomegalovirus (CMV) screening.  
• What things can I do to lower 
the risk of getting an 
infection? Ask your doctor 
about things like water, food, 
safe sex, travel, and avoiding 
second hand smoke. 
• Are my vaccines up-to-date? 
 
EYES QUESTIONS TO ASK YOUR 
DOCTOR AND YOUR NOTES 
  Wear sunglasses every time you go outside. 
  Vision screening by your eye doctor 1 time every year to check 
how well you can see 
  Because you have a history of GVHD, you may need to have 
eye exams more often.  
• Do I need to see an eye 
specialist? 
• How often should I have eye 
tests? 
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RECOMMENDATIONS FOR YOUR ROUTINE SCREENING AND PREVENTIVE CARE 
  If you have eye pain, dryness, change in vision, sensitivity to 
light, or watery eyes, you need to have an eye exam. Your 
doctor will tell you if you need treatment. 
MOUTH QUESTIONS TO ASK YOUR 
DOCTOR AND YOUR NOTES 
It’s important that you brush and floss everyday to prevent 
infections. Also, your doctor needs to check your mouth to make 
sure your teeth, tongue and throat are healthy and there are no 
signs of oral cancer.  
  General mouth, teeth, tongue, and throat exam at least 1 time 
every year 
  Because you have a history of GVHD, you need to have 
mouth, teeth, tongue, and throat exams at least 2 times every 
year. Talk to your doctor and dentist about when you should 
have these check-ups.   
  Because you had total body irradiation (TBI), you need to 
have mouth, teeth, tongue, and throat exams at least 2 times 
every year. Talk to your doctor about when you should have 
these check-ups. 
  Dental exam and tooth cleaning by a dentist at least 1 time 
every year 
  Tell your doctor and dentist if you have dry mouth. This 
could be a side effect of medications you are taking or a sign 
of GVHD. 
• Other than not smoking, and 
brushing and flossing every 
day, are there other things I 
can do to keep my mouth 
healthy? 
• Do I need to take medicine 
before I have any dental 
procedures? 
LUNGS QUESTIONS TO ASK YOUR 
DOCTOR AND YOUR NOTES 
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RECOMMENDATIONS FOR YOUR ROUTINE SCREENING AND PREVENTIVE CARE 
  Lung exam at least 1 time every year  
If you have problems breathing or have had breathing problems in 
the past, you may need more tests such as: 
  Pulmonary function tests 
  Chest x-ray 
  CT scan 
  Because you have a history of GVHD, you might need to have 
lung exams and pulmonary function tests more often. Talk to 
your doctor about when you should have these check-ups. 
  Don’t smoke or use tobacco. Stay away from places where 
people usually smoke. 
• What can I do to minimize my 
risk of getting infections? 
• What tests should I have and 
how often? 
• What can I do to help me quit 
smoking? 
 
HEART AND BLOOD VESSELS QUESTIONS TO ASK YOUR 
DOCTOR AND YOUR NOTES 
Even many years after transplant heart problems can occur.  
  Blood pressure checked every time you visit the clinic (also 
see Kidneys and Bladder section)  
  Blood tests to check your cholesterol level at least 1 time every 
year. This includes triglycerides, LDL, and HDL  
You may need these tests more often if you had heart or blood 
vessel problems before or after transplant.  
• How can I minimize my risk 
of heart disease? 
• My goals: 
o Blood pressure: 
_________ 
o Cholesterol:       
_________ 
o Weight:             
_________ 
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RECOMMENDATIONS FOR YOUR ROUTINE SCREENING AND PREVENTIVE CARE 
LIVER QUESTIONS TO ASK YOUR 
DOCTOR AND YOUR NOTES 
  Liver function blood tests (to see if your liver is working 
well) at least 1 time every year 
  If you had red blood cell transfusions, you may need to have a 
blood ferritin test to check the level of iron in your blood.  
• If you have too much iron in your blood or your test results 
are abnormal, your doctor might do more tests. 
• If you have a hepatitis B or C infection, your doctor will 
watch it closely.  
• Do I need any other tests to 
make sure my liver is working 
well? 
• Do I need to see a liver 
specialist? 
KIDNEYS AND BLADDER QUESTIONS TO ASK YOUR 
DOCTOR AND YOUR NOTES 
  Blood pressure checked every time you visit the clinic. High 
blood pressure (hypertension) can damage your kidneys.  
  Kidney test at least 1 time every year which includes testing: 
• Protein levels in your urine 
• Nitrogen levels in your blood (BUN) and creatinine test 
If your test results show that your kidneys are not working 
properly, you might need further tests such as:  
  Kidney ultrasound 
  Kidney biopsy  
If you have kidney disease, you should: 
• What are things I can do now 
to keep my blood pressure in 
check?  
• If my blood pressure is high, 
what can I do to get it under 
control?  
• Do I need to see a kidney 
specialist? How often?  
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RECOMMENDATIONS FOR YOUR ROUTINE SCREENING AND PREVENTIVE CARE 
  Avoid medicines and substances (foods, herbs, vitamin 
supplements) that can hurt your kidneys  
  See a kidney doctor 
  Because you have a history of GVHD, you might need to have 
your kidneys checked more often. Also, you can get urinary 
tract infections (UTI) more often.  
MUSCLES AND JOINTS QUESTIONS TO ASK YOUR 
DOCTOR AND YOUR NOTES 
  If you have myopathy (weak muscles), muscle pain, or joint 
pain, schedule an appointment with your doctor right away. 
Your doctor will check your muscles to find out if you need 
treatment. 
Because you have a history of GVHD and have taken steroids 
(such as prednisone), talk to your doctor about clinical exam for: 
  Muscle strength  
  Range of motion in your joints 
• Do I need to see a physical 
therapist? 
• How can I build my muscle 
strength? 
 
BONES QUESTIONS TO ASK YOUR 
DOCTOR AND YOUR NOTES 
Transplant can cause low levels of bone density. You can develop 
bone diseases if your density levels get too low (such as 
osteopoenia and osteoporosis). As a woman and because you’ve 
had an allogeneic transplant and taken steroids, you’re more likely 
to have low levels of bone density. To help keep your bones 
healthy, you need to have: 
  Bone density scan (test) every year. If your scan is abnormal, 
you might need more scans. 
• Do I need a bone density scan 
at all? If so, how often? 
• What are the ways to help me 
prevent bone density loss? 
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RECOMMENDATIONS FOR YOUR ROUTINE SCREENING AND PREVENTIVE CARE 
SKIN QUESTIONS TO ASK YOUR 
DOCTOR AND YOUR NOTES 
  Do a self-exam of your skin every month to check for any 
changes (for example, rash, unusual growth, or patch).  
• If you see unusual growth or patch on your skin, tell your 
doctor as soon as possible. Your doctor will refer you to a 
skin specialist.  
  Use sunscreen with SPF 15 or higher every time you go 
outside. Reapply at least every 2 hours, or more often if you’re 
sweating or in and out of the water. 
  Avoid direct sunlight. Wear a broad-brimmed hat or use a 
large umbrella to protect your skin from the sun. 
• How do I do a self-exam of 
my skin?  
• Should I use any special 
soaps or lotions? 
• Do I have scleroderma? 
Fasciitis? 
 
NERVOUS SYSTEM QUESTIONS TO ASK YOUR 
DOCTOR AND YOUR NOTES 
The nervous system includes your brain, spinal cord and nerves. 
Sometimes after transplant, patients have changes or problems 
with how their nervous system works. 
  Clinical exam by your doctor at least 1 time every year to 
check for changes or problems 
  Tell your doctor right away if you have trouble with things like 
your memory, concentration, or making decisions. Your doctor 
will tell you if you need more tests and/or treatment. 
• How do I know when to call 
the clinic about symptoms I’m 
having? 
ENDOCRINE ORGANS (THYROID, GROWTH AND SEX HORMONES) QUESTIONS TO ASK YOUR 
DOCTOR AND YOUR NOTES 
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RECOMMENDATIONS FOR YOUR ROUTINE SCREENING AND PREVENTIVE CARE 
To make sure your endocrine system is working well, you should 
have these tests at least 1 time every year: 
  Blood test to check how well your thyroid is working  
  Blood tests to assess your sex hormone levels 
  Fasting glucose (sugar) test to check for Diabetes (where 
you do not eat or drink anything before the test) 
You might need to see an OB/GYN (women’s health doctor) to 
talk about hormone replacement therapy.  
• Do I need to see an OB/GYN 
specialist? 
GENITALS AND SEXUAL HEALTH QUESTIONS TO ASK YOUR 
DOCTOR AND YOUR NOTES 
  To stay healthy you should have a gynecology exam at least 1 
time every year 
Tell your doctor if you have any of these symptoms: 
  Low sex drive 
  Erectile dysfunction or impotence  
  Hot flashes 
  Vaginal dryness  
  Vaginal pain or bleeding after sexual intercourse 
These could be signs of low sex hormone levels, menopause or 
GVHD. You might go into early menopause after transplant, even 
if you’re young. Your doctor will tell you if you need more tests 
and/or treatment.  
• Should I do a breast/testicular 
self exam? How often? What 
should I be looking for? 
• Do I need to be tested for 
sexually transmitted 
diseases? 
• How can I stay sexually 
healthy after transplant?  
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RECOMMENDATIONS FOR YOUR ROUTINE SCREENING AND PREVENTIVE CARE 
FERTILITY AND FAMILY PLANNING QUESTIONS TO ASK YOUR 
DOCTOR AND YOUR NOTES 
Transplant can lower your ability to have children.  
  Ask your doctor about your chances of being able to have 
children after transplant.  
  If you want to have children in the future, ask your doctor to 
refer you to a fertility doctor.  
  Talking about fertility can be very emotional. See the 
Emotional Health section for ways to help you sort out your 
feelings.  
• Should my partner or I be 
using birth control?  
• What type of birth control is 
best for my partner or me? 
 
EMOTIONAL HEALTH QUESTIONS TO ASK YOUR 
DOCTOR AND YOUR NOTES 
Going through transplant is a very emotional experience. Your 
feelings and needs will change a lot, maybe even every day. It’s 
important that you talk openly and regularly with your doctor, 
family and friends.  
Here are some questions to help you sort out your feelings and talk 
about them with people you trust:   
• How do you feel overall? Better or worse than expected? How 
do you feel today? How is it different from how you felt 
yesterday?  
• Are you worried or angry about anything?  
• Are you eating well?  
• How is your energy level? Are you tired more often or do you 
easily become tired? Are you sleeping well?  
• What can I do to make sure 
I’m taking care of myself 
emotionally?  
• Should I see another doctor, 
therapist, or counselor about 
my emotional health? 
• Are there any counseling or 
support groups in my area that 
I could join? 
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RECOMMENDATIONS FOR YOUR ROUTINE SCREENING AND PREVENTIVE CARE 
• Have you noticed if anything makes you feel better or worse? 
• How are your relationships with your loved 
one/partner/spouse? Family? Close friends? Are you talking 
with them about any relationship problems? 
• Are you asking for help when you need it?  
DIET AND NUTRITION QUESTIONS TO ASK YOUR 
DOCTOR AND YOUR NOTES 
To stay healthy and help your immune system fight disease, eat a 
healthy diet that includes many different foods. General guidelines 
for a balanced diet include:     
  Vegetables, fruits and whole grains - 2-3 cups every day  
  Protein  - 3-6 ounces every day of cooked lean meats like fish 
and chicken (or 46-56 grams of protein)   
  Dairy 3 cups every day (low-fat or fat-free)  
  Drink at least eight 8-ounce glasses of fluid every day to stay 
hydrated. You need to drink more water when: 
• It’s hot outside  
• You exercise or are more physically active 
• You have a fever or diarrhea or vomit (throw up) 
  Avoid foods with lots of processed (fake) sugar or saturated 
(bad) fat like candy or soda 
After transplant, you might experience changes in taste, loss of 
appetite, nausea or other symptoms that make it hard to keep a 
healthy diet. Talk to your doctor about your symptoms. 
• Should I see a dietician (diet 
and nutrition expert)? 
• Should I be concerned about 
any new allergies? 
• If I have trouble with GVHD 
of my GI tract, can you help 
me make a plan to maintain a 
healthy diet?  
• How can I keep a healthy diet 
and weight? 
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RECOMMENDATIONS FOR YOUR ROUTINE SCREENING AND PREVENTIVE CARE 
GENERAL HEALTH QUESTIONS TO ASK YOUR 
DOCTOR AND YOUR NOTES 
It’s important to take care of yourself and follow your doctor’s 
orders to stay healthy and well. To make sure you are staying 
healthy overall, follow these general lifestyle practices:  
  Use alcohol in moderation (less than 2 drinks a day) 
  Stay physically active (2.5 hours each week of moderate 
exercise)   
  Don’t smoke or use chewing tobacco 
  Stay away from places where people usually smoke 
  Don’t let people smoke in your house or car 
Smoking cigarettes or using tobacco hurts nearly every organ in 
the body, especially your lungs and heart. It can also cause new 
cancers. 
• What are some exercises I 
can do to stay physically 
active? 
• Are medications to help me 
quit smoking an option? If so, 
which ones? How long will I 
be on them? What are the side 
effects of the medications? 
• Where can I go for counseling 
or a support group to quit 
smoking? 
NEW CANCERS QUESTIONS TO ASK YOUR 
DOCTOR AND YOUR NOTES 
New cancers can develop because you’ve had chemotherapy 
and/or radiation, TBI and have a history of GVHD. You need to 
have screenings at least 1 time every year for: 
  Breast cancer (mammography every 1 to 2 years       
starting at age 25)  
  Cervical cancer 
  Colorectal cancer (starting at age 50 or earlier if you have a 
family history of colorectal cancer) 
  Skin cancer 
• What is my risk for getting 
new cancers? 
• How can I lower my risk of 
getting new cancers? 
• How do I do a self-exam of 
my skin? How often? What 
should I be looking for? 
• Would I benefit from annual 
skin exams? 
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YOUR CARE TEAM INFORMATION 
Transplant doctor: 
Phone: 
Primary care doctor: 
         Clinic name: Phone: 
Oncology (cancer) doctor: 
         Clinic name: Phone: 
Ophthalmologist (eye specialist):  
         Clinic name: Phone: 
 OB/GYN (women’s health specialist): 
         Clinic name: Phone: 
Physical Therapist: 
         Clinic name: Phone: 
Dentist: 
         Clinic name: Phone: 
Other doctor: 
         Clinic name: Phone: 
Other doctor: 
         Clinic name: Phone: 
Other doctor: 
         Clinic name: Phone: 
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YOUR TREATMENT NOTES 
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Individualized Care Plans for HCT Survivors  
Study funding provided by the Patient Centered Outcomes Research Institute (PCORI) and 
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Marrow Transplant (RCI BMT).  
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Congratulations on the one-year anniversary of your blood and marrow transplant (transplant), 
also known as HCT. Thank you for joining the Individualized Care Plans for HCT Survivors 
study. This folder contains your study materials: 
• Your personalized care plan 
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• Actions you can take to get the most out of your care plan 
• How to get answers to your questions 
A survivorship care plan includes a summary of your transplant treatment and plan for follow-up 
care. You and your doctors can use this information to make decisions together about your care. 
Transplant follow-up care is important to protecting your heath, even many years after 
transplant. 
Your transplant center reviewed the information in this care plan. For this study, treatments or 
issues that you might have had before transplant are not included in the care plan. Please contact 
your transplant center or hematologist/oncologist (cancer doctor) for your questions about 
treatment before transplant. 
We will use your feedback to improve HCT survivorship care plans in the future. 
Sincerely, 
Elizabeth A. Murphy 
Elizabeth Murphy, RN, EdD 
Principal Investigator 
K. Scott Baker  
K. Scott Baker, MD, MS 
Co-Principal Investigator 
Navneet S. Majhail  
Navneet Majhail, MD, MS  
Co-Principal Investigator
PSCORI SCP template mock up text 
V2.0  NMDP IRB Approved 06/18/2014  
Inside Right Panel 
Glossary 
Bone density scan — An imaging (picture) test that looks for abnormal (or unhealthy) areas in 
your bones. For this test, you are given a small amount of a fluid in your arm. The fluid is a 
radioactive contrast material (like a dye) that settles in abnormal areas of the bones. The dye can 
then be seen in pictures. When bone density is low, your bones become more porous (full of 
holes) and brittle. When this happens, you have a higher risk of breaking them.  
Cytomegalovirus (CMV) — A type of herpes virus that can cause infections (for example, 
pneumonia). 
Endocrine organs — Endocrine organs release hormones into your blood to manage body 
functions like your mood and growth. Endocrine organs include the thyroid, pituitary, and 
pancreas glands. 
Fasciitis — Inflammation (redness and swelling) of the connective tissue that surrounds 
muscles, blood vessels, and nerves. Often patient get fasciitis and hardening of the skin (see 
Scleroderma) at the same time. 
Fertility — A person’s ability to have children 
Gastrointestinal (GI) tract — Also called the digestive tract. It is made up of body organs that 
process the food you eat. The GI tract includes the throat, stomach, and intestines.  
Graft-Versus-Host Disease (GVHD) — A post-transplant condition where the donor cells 
attack the patient’s tissues or organs. 
HDL cholesterol — High-density lipoprotein or HDL is known as “good” cholesterol because it 
helps to remove “bad” cholesterol (LDL) and keep your blood vessels healthy (see LDL).   
Immunosuppressant drugs —  Immunosuppressant drugs work to lower the strength of your 
immune system. The main use of these drugs is to lower the body’s ability to reject the 
transplanted bone marrow, cord blood or peripheral blood stem cells. Immunosuppressant drugs 
are usually given to treat GVHD.   
Kidney disease — When your kidneys don’t properly filter toxins (or poisons) and waste 
products from your blood. 
Kidney filtration levels test — Measures how much liquid flows through your kidneys. This 
test is used to see if you have chronic kidney disease. 
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LDL cholesterol — Low-density lipoprotein or LDL is known as “bad” cholesterol. When you 
have too much LDL is your blood, it can form a thick, hard deposit. If a clot forms and blocks an 
artery, you might have a heart attack or stroke. 
Mammography — An imaging (picture) test to see if you have breast cancer. 
Meningitis — Inflammation of the membranes covering your brain and spinal cord. This is 
caused by viruses, fungi or bacteria. 
Myopathy — Muscle disease and weakness. Steroids are used to treat chronic GVHD, but might 
result in muscle weakness, especially in your lower body (for example, your legs and feet). 
Osteopenia — Thinning of your bone tissue. Bones are weak with Osteopenia, but not as weak 
as with Osteoporosis. Patients develop Osteopenia before Osteoporosis. 
Osteoporosis — A lot of thinning of your bone tissue, causing very weak bones. Osteoporosis 
can cause pain and lead to broken bones. 
Oral cancer — Cancer of the mouth. 
Pneumonia — Inflammation of the lungs caused by viruses, fungi, or bacteria. 
Pulmonary function tests — A group of tests to measure how well the lungs are working. 
Range of motion — A test to find out if a joint (such as elbow, hip, wrist) can move properly 
and in all normal directions. 
Scleroderma — When your skin becomes hard, thick, and tight. This can lead to weak muscles, 
stiff joints or pain in your joints. 
Thyroid — A gland that controls your body’s metabolism. Metabolism is how quickly your 
body uses energy from the food you eat. 
Fold-in Panel 
Take action  
  Schedule twelve-month check-up appointments with your transplant doctor or your 
hematologist/oncologist.  
  Review the tests, procedures and questions to ask your doctor listed in the care plan inside.  
  Write down questions or issues you’d like to discuss at your appointments.  
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  Ask your doctor if there are other recommendations unique to your situation.  
  Bring this care plan to all of your appointments.  
  At your appointment, ask your doctor if you need to schedule appointments with other health 
care providers (for example, eye doctor, dentist, physical therapist, OB/GYN, counselor or 
other specialists).  
  You might have more than 1 doctor. Talk with your doctors and encourage them to speak 
with each other. This will help you know who to call when you have new symptoms or to 
schedule checkup appointments. 
Share with your doctor  
  Review this guide with them at your next appointment.  
  Ask them to make a copy for your medical record. 
 
For questions or more information 
You might have questions about your care plan. For answers to these questions, contact your 
transplant center. The name and phone number for your transplant center are listed on the care 
plan inside. 
You might have questions about this study. For answers to these questions, contact the 
Investigator at your transplant center. This information is provided in your consent form and the 
patient information sheet. You can also contact the Center for International Blood and Marrow 
Transplant Research (CIBMTR) study team by: 
Phone: 1-800-526-7809 Ext. 4368 (toll-free)  
E-mail: SCP_SRGTeam@nmdp.org 
